Supplemental material
Open access
3,654
Views
4
CrossRef citations to date
0
Altmetric
Neurology
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses
Imtiaz A. Samjooa EVERSANA, Burlington, Canadahttps://orcid.org/0000-0003-1415-8055
, Evelyn Worthingtona EVERSANA, Burlington, Canadahttps://orcid.org/0000-0003-1659-2082
, Anja Haltnerb EVERSANA, Sydney, Canadahttps://orcid.org/0000-0002-9829-7791
, Paul Spinb EVERSANA, Sydney, Canadahttps://orcid.org/0000-0002-4622-3547
, Christopher Drudgea EVERSANA, Burlington, Canadahttps://orcid.org/0000-0001-9721-3069
, Chris Cameronb EVERSANA, Sydney, CanadaCorrespondence[email protected]
https://orcid.org/0000-0003-3613-760X
, https://orcid.org/0000-0003-3613-760X
Róisín Brennanc Novartis Ireland, Dublin, Ireland
, Frank Dahlked Novartis Pharma AG, Basel, Switzerlandhttps://orcid.org/0000-0003-3333-6291
& Nicholas Adlardd Novartis Pharma AG, Basel, Switzerlandhttps://orcid.org/0000-0001-6912-1685
show all
Pages 1933-1944
|
Received 06 Jul 2021, Accepted 11 Aug 2021, Published online: 26 Aug 2021
Related Research Data
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses
Source:
Taylor & Francis
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses
Source:
Taylor & Francis
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses
Source:
Taylor & Francis
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.